Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer By Ogkologos - August 12, 2025 385 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the IoN study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Could food improve cancer treatment? – That Cancer Conversation May 30, 2023 Stereotactic Radiosurgery Not Superior in Terms of Pain Response Compared with... April 26, 2023 More than 65,000 people are left waiting to find out if... May 8, 2022 Adjuvant Pembrolizumab Plus Chemotherapy Improves DFS in Patients with Newly-Diagnosed, High-Risk... October 1, 2024 Load more HOT NEWS Favourable Benefit-Risk Profile of Trastuzumab Deruxtecan in Patients with HER2-positive MBC... Should People Over Age 75 Be Screened for Colorectal Cancer? FDA Grants Accelerated Approval to Ponatinib with Chemotherapy for Newly Diagnosed... Veteran Dresses As Captain America & Brings Joy To Children In...
